Pulmonx received FDA pre-market approval for a drug and plans to present its findings at a conference in Boston.
1 report, 1 independent
Updated Jul 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pulmonx received FDA pre-market approval for a drug and plans to present its findings at a conference in Boston.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Pulmonx (United States)
company in Redwood City, United States
Nothing else this week.
- FDA
Related events
- InflaRx is seeking discussions with the FDA and collaborating with Staidson BioPharmaceuticals on clinical trials.
- Argenx SE announced it is listed on Nasdaq and is seeking FDA priority review and approval.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
Coverage
Newest first; wire copies grouped- GlobeNewswirePulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference REDWOOD CITY, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a gl